BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing
Neuro-Oncology Practice · 01.08.2026 · 13 (4) · 823-827
DOI: 10.1093/nop/npag035 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuro-Oncology Practice, online erschienen am 17.04.2026. Verfasst von Bertrand Baussart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Rathke cleft cysts are benign sellar lesions with a substantial risk of postoperative recurrence. In contrast to papillary craniopharyngiomas, oncogenic BRAF mutations are exceptionally reported in Rathke cleft cysts (RCCs), and the therapeutic relevance of targeted inhibition remains unknown. Case summary A 51-y-old man presented with a giant cystic suprasellar lesion involving the optochiasmatic and subfrontal regions. Following incomplete surgical resection, histopathological analysis confirmed the diagnosis of Rathke’s cleft cyst. Molecular profiling identified a somatic BRAF p. V600E mutation present in a subclonal population. Rapid recurrence occurred 3 months postoperatively. Combined BRAF/MEK inhibition with dabrafenib and trametinib was initiated, leading to a marked reduction in cyst volume on serial MRI, further enhanced after dose escalation. Treatment was well tolerated, with complete symptom resolution and no endocrine impairment.
Conclusion
This report describes the first adult BRAF-mutant RCC responding to BRAF/MEK-targeted therapy, supporting molecular profiling to guide personalized management in recurrent or high-risk RCCs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- CNRS, INSERM, Institut Cochin, Université Paris Cité, Paris, France.
- Department of Functional and Diagnostic Neuroradiology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
- Department of Endocrinology and Reproductive Medicine, Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, CRMERC, Endo-ERN, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University…
- Department of Medical Genetics, Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Lariboisière University Hospital, Paris, France.
ORCID-Profile: Bertrand Baussart, Ahmed Idbaih, Chiara Villa
Zitieren
APA
Baussart, B., Leclercq, D., Courtillot, C., Coulet, F., Tran, S., Idbaih, A., & Villa, C. (2026). BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing. Neuro-Oncology Practice, 13(4), 823-827. https://doi.org/10.1093/nop/npag035
Vancouver
Baussart B, Leclercq D, Courtillot C, Coulet F, Tran S, Idbaih A, et al. BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing. Neuro-Oncology Practice. 2026;13(4):823-827. doi:10.1093/nop/npag035
BibTeX
@article{Baussart2026,
author = {Baussart, Bertrand and Leclercq, Delphine and Courtillot, Carine and Coulet, Florence and Tran, Suzanne and Idbaih, Ahmed and Villa, Chiara},
title = {BRAF–MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing},
journal = {Neuro-Oncology Practice},
year = {2026},
volume = {13},
number = {4},
pages = {823--827},
doi = {10.1093/nop/npag035}
}
EUVIMED